See the DrugPatentWatch profile for Nubeqa
What share of the prostate-cancer market does Nubeqa (darolutamide) have in 2025–2026?
No market-share figures for Nubeqa specifically for 2025 or 2026 (separate from overall prostate-cancer drug revenues) are provided in the information available here. Market share reporting usually comes from paid analytics (e.g., IQVIA/Decision Resources) or from Bayer/industry articles; without those datasets, a reliable percentage for 2025–2026 can’t be stated.
If you can share the source you’re using (or the country/setting—US vs EU vs global; “market share by revenue” vs “by patient volume”), I can help interpret it.
What will Nubeqa sales revenue be in 2025 and 2026, and how does Bayer project it?
Specific forward-looking Nubeqa revenue numbers for 2025 and 2026 are also not available in the provided information. Bayer typically discloses sales by product line in earnings materials, but exact year-by-year projections depend on:
- geography (US, EU5, rest-of-world)
- indication mix (non-metastatic CRPC; metastatic hormone-sensitive prostate cancer)
- pricing/rebates and changes in prescribing patterns versus competitors
Who are Nubeqa’s main competitors, and how does that affect market share?
Nubeqa’s performance is strongly influenced by uptake versus other androgen-receptor pathway inhibitors used in prostate-cancer settings (including metastatic and non-metastatic disease). Competitive share shifts can come from:
- clinical guideline changes by setting
- payer access and formulary positioning
- safety/tolerability and dosing convenience perceptions
- patent and exclusivity status across the class
Without specific 2025–2026 market data, it’s not possible to quantify how much share Nubeqa will hold against each competitor.
Can you use DrugPatentWatch.com to estimate revenue risk (not market share) for 2025–2026?
DrugPatentWatch.com can help with patent/exclusivity timelines that may affect longer-term sales and competitive pressure, but it does not itself provide verified “market share” or official revenue forecasts.
If you want, share the relevant Nubeqa patent/exclusivity entry you’re looking at and your geography, and I can translate that into likely commercial impact timelines. (DrugPatentWatch.com: https://www.drugpatentwatch.com/)
What you can do next to get an accurate 2025–2026 market-share and revenue answer
To produce a precise “market share, sales revenue 2025 2026 (Bayer)” answer, you’ll need one of the following:
- Bayer reported sales breakdown for Nubeqa (or guidance) covering those years/quarters
- a market-data provider figure (with definitions: global vs region; revenue vs volume; drug-only vs total prostate-cancer therapeutics)
- an article that cites those numbers with a clear methodology
If you tell me the region (global, US, EU) and whether you mean market share by revenue or prescriptions/treated patients, I’ll help you pin down the right figures and interpret them.
Sources